NT pro-NB as a marker of the pneumonia severity in children.

J. Lange (Warsaw, Poland), H. Marczak (Warsaw, Poland), K. Krenke (Warsaw, Poland), J. Peradzynska (Warsaw, Poland)

Source: International Congress 2019 – Paediatric respiratory infections around the world: Tuberculosis, pneumonia and others
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Lange (Warsaw, Poland), H. Marczak (Warsaw, Poland), K. Krenke (Warsaw, Poland), J. Peradzynska (Warsaw, Poland). NT pro-NB as a marker of the pneumonia severity in children.. 994

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes
Source: Virtual Congress 2021 – Acute paediatric respiratory infections
Year: 2021


Correlation between pneumonia severity index and mortality within 30 days after the diagnosis of community-acquired pneumonia in elderly subjects
Source: Eur Respir J 2006; 28: Suppl. 50, 741s
Year: 2006

The pneumonia severity index (PSI) do not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008


Is severity index enough to assess hospital admission of community-acquired pneumonia (CAP) patients?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006


Lactate is an independent marker of severity in hospitalised patients with community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005

I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP)
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010

Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013



C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005

Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010

Community-acquired pneumonia (CAP) in alcoholic patients (AL): differences in aetiology and severity
Source: Eur Respir J 2002; 20: Suppl. 38, 560s
Year: 2002

Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002



Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia?
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019


Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005

Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012


Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006


Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged >=75 yrs
Source: Eur Respir J 2001; 17: 200-205
Year: 2001



Physicians should not use the pneumonia severity index (PSI) or CRB-65 in deciding the need for hospitalization in cancer patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 41s
Year: 2007

Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007